enicepatide | Search

Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

10 results for “enicepatide”

Trials

A Study of Enicepatide (CT-388) in Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity

469 participants · First posted Jul 29, 2024

Active, not recruiting

A Study of Enicepatide (CT-388) in Participants Who Are Overweight or Obese With Type 2 Diabetes Mellitus

447 participants · First posted Oct 8, 2024

A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes

1,600 participants · First posted Jan 20, 2026

News

Roche's Enicepatide Hits Both Phase II Endpoints in Type 2 Diabetes, With 2.65% HbA1c Drop at 24 mg

Roche's Enicepatide Cuts HbA1c 2.65% and Weight 15.5% at 48 Weeks in Phase II Type 2 Diabetes Trial

Genentech's dual GLP-1/GIP agonist enicepatide cuts HbA1c 2.65% and weight 15.5% at 48 weeks in Phase II T2D trial